Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irofulven second generation - Lantern Pharma

Next Previous
Drug Profile

Irofulven second generation - Lantern Pharma

Alternative Names: Hydroxymethylacylfulvene; Irofulven-2; Irofulven-second-generation-Lantern-Pharma; LP 184; STAR-001

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Lantern Pharma
  • Class Antineoplastics; Cyclopropanes; Indenes; Sesquiterpenes; Small molecules; Spiro compounds
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors; RNA polymerase II inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Glioblastoma; Pancreatic cancer; Teratoma; Triple negative breast cancer; Rhabdoid tumour
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Rhabdoid tumour

Most Recent Events

  • 29 May 2025 Adverse events, pharmacokinetics and pharmacodynamics data from preclinical trials in Rhabdoid tumour released by Lantern Pharma
  • 29 May 2025 Lantern Pharma plans a phase I trial for Brain cancer (In neonates, In infants, In children, In adolescents) (Parenteral) in winter 2025 or early 2026
  • 15 May 2025 Lantern Pharma and Starlight plans a phase Ib/IIa trial for Glioblastoma (Monotherapy, Combination therapy) in late 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top